Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Manual for Well known rough terrain Vehicles - 2Intriguing Social Unesco World Legacy Locales All over The Planet
- 3Change Your Physical make-up: Compelling Activities for Muscle Building
- 4When will the Epstein files be released — and will they reveal anything new?
- 5Figure out How to Amplify the Resale Worth of Your Kona SUV
- Exploring the Gig Economy: Examples from Consultants
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- What are parents to do as doctors clash with Trump administration over vaccines?
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- The 10 Most Famous Works of art Ever
- Amazon sued over 'punitive' handling of employee absences
- Step by step instructions to Protect Your Speculations with Cd Rates
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Which Brilliant Home Gadget Can't You Reside Without?
